脂肪肝
脂肪变性
肝星状细胞
疾病
内科学
脂毒性
化学
纤维化
内分泌学
医学
脂肪酸
生物化学
生物
胰岛素抵抗
肥胖
作者
Rachel B. Wilson,Yun Jin Chen,Brian G. Sutherland,Cynthia G. Sawyez,Richard Zhang,Taylor Woolnough,Alexandra M. Hetherington,Kia M. Peters,Krisha Patel,John Paul Kennelly,Kelly‐Ann Leonard,Meg Schuurman,René L. Jacobs,Rennian Wang,Nica M. Borradaile
标识
DOI:10.1016/j.phrs.2020.105208
摘要
Inhibition of eukaryotic elongation factor 1A1 (EEF1A1) with the marine compound didemnin B decreases lipotoxic HepG2 cell death in vitro and improves early stage non-alcoholic fatty liver disease (NAFLD) in young genetically obese mice. However, the effects of didemnin B on NAFLD in a model of long-term diet-induced obesity are not known. We investigated the effects of didemnin B on NAFLD severity and metabolic parameters in western diet-induced obese mice, and on the cell types that contribute to liver inflammation and fibrosis in vitro. Male 129S6 mice were fed either standard chow or western diet for 26 weeks, followed by intervention with didemnin B (50 μg/kg) or vehicle by intraperitoneal (i.p.) injection once every 3 days for 14 days. Didemnin B decreased liver and plasma triglycerides, improved oral glucose tolerance, and decreased NAFLD severity. Moreover, didemnin B moderately increased hepatic expression of genes involved in ER stress response (Perk, Chop), and fatty acid oxidation (Fgf21, Cpt1a). In vitro, didemnin B decreased THP-1 monocyte proliferation, disrupted THP-1 monocyte-macrophage differentiation, decreased THP-1 macrophage IL-1β secretion, and decreased hepatic stellate cell (HSteC) proliferation and collagen secretion under both basal and lipotoxic (high fatty acid) conditions. Thus, didemnin B improves hepatic steatosis, glucose tolerance, and blood lipids in obesity, in association with moderate, possibly hormetic, upregulation of pathways involved in cell stress response and energy balance in the liver. Furthermore, it decreases the activity of the cell types implicated in liver inflammation and fibrosis in vitro. These findings highlight the therapeutic potential of partial protein synthesis inhibition in the treatment of NAFLD.
科研通智能强力驱动
Strongly Powered by AbleSci AI